The Goal of the Mayo SPORE in Brain Cancer Career Development Program (CDP) will continue into this next grant period - The contribution of knowledgeable and well-trained scientists experienced in multidisciplinary research in, and informed of the public health importance of, primary brain tumors. The premise of this program is that such scientists will advance and significantly impact the nation's brain tumor agenda. The primary objective of the Program is to train young investigators in translational, multidisciplinary brain tumor research. To meet these objectives, the SPORE CDP will have the following components: (1) A stringent candidate selection system;(2) Comprehensive guidance by a scientific group comprised of investigators with expertise in the relevant area of interest and extensive experience as research mentors; and, (3) Prescribed training and education;and, (4) Collaboration with investigators within this SPORE, and with investigators within the other Mayo SPOREs. The CDP builds on its success in the first grant period amplified by Program-specific re-corrections. The CDP will be continue to be immersed in a rich cancer-, neuroscience-, and neurooncology-specific educational environment that includes CDPs of five other Mayo SPORE grants, a Cancer Center Education Portfolio, six NIH-supported cancer-focused T32 training grants, and a Clinical Translational Sciences Award (CTSA). A new Mayo Foundation Office of Research Postgraduate Affairs provides institutional infrastructure to all NIH-funded training and education enterprises including this CDP.

Public Health Relevance

The Mayo SPORE's CDP will provide for integrated training and education to new investigators committed to careers in translational research of primary brain tumors. The format is designed to provide breadth and flexibility to awardees who require additional research knowledge and skills in order to compete for independent extramural grant support and contribute to the Mayo SPORE in Brain Cancer. The CDP will continue as a research experience under the mentorship of established SPORE investigators and supported by SPORE-funded Administrative, Biostatistics, Pathology, Animal, and Clinical Cores.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications